Clinical trial
Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer
NCT00389610 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00389610 |
|---|---|
| Title | Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer |
| Official title | A Safety and Efficacy Trial of Vaccine Boosting With Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | The Skip Viragh Foundation National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | GVAX pancreas vaccine |
| Enrollment | 56 |
| Start date | Sep 11, 2006 |
| Primary completion | Oct 11, 2021 |
| Completion | Dec 10, 2022 |
| First posted | Oct 19, 2006 |
| Last update posted | Oct 26, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: